GTCR to Buy Zentiva From Advent in €4.1B Generics Deal - InforCapital

GTCR, a US-based private equity firm with deep healthcare expertise, has agreed to acquire Zentiva from Advent International in a deal valued at approximately €4.1 billion, including debt. The acquisition marks one of the largest generics pharma transactions in Europe this year.

Zentiva serves over 100 million people across more than 30 countries, providing affordable, high-quality medicines across therapeutic areas. Since its carve-out from Sanofi in 2018, Advent has more than doubled the company’s revenue and EBITDA through a mix of organic growth, R&D investments, and strategic acquisitions.

GTCR plans to accelerate Zentiva’s development through product innovation, increased manufacturing scale, and new acquisitions. The firm brings a long track record of success in healthcare, having backed dozens of platforms in pharmaceuticals, diagnostics, and specialty care.

According to Advent, Zentiva’s transformation from a non-core asset into a market-leading independent company reflects its strategy of backing management teams to grow platforms at scale. The deal is expected to close in early 2026, subject to regulatory approvals.

Similar Transactions in the Pharma Sector:

• In July 2024, CVC Capital Partners sold its stake in Alvogen’s generics unit to AbbVie for $2.3 billion, reinforcing the trend of large pharma acquiring mature generics businesses with strong pipelines and global reach.
• Permira and Marblegate acquired STADA Arzneimittel for €5.3 billion in 2023. STADA, another major European generics player, benefited from a sharp focus on branded generics and specialty medicines.
• In 2022, Advent and Avista Capital Partners jointly invested over $2 billion in India’s RA Chem Pharma and subsequently merged it with other portfolio companies to create a unified B2B pharmaceutical manufacturing powerhouse.
• Blackstone and Carlyle have also been active in the healthcare space — notably bidding for Viatris’s API and generics divisions in 2023, although the deal did not materialize due to valuation disagreements.

These deals reflect growing investor appetite for generics and specialty pharma platforms that combine manufacturing scale, regulatory competence, and commercial agility. With aging populations and rising healthcare costs, access to affordable medicines remains a long-term growth theme.

Zentiva is expected to play a central role in this trend under GTCR’s ownership, leveraging its broad portfolio, pan-European footprint, and growing R&D pipeline to deliver value for both patients and investors.